Novel Betulin-1,2,4-Triazole Derivatives Promote In Vitro Dose-Dependent Anticancer Cytotoxicity

Abstract

Betulin is a birch bark-derived lupane-type pentacyclic triterpene with a wide spectrum of biological activities. Given their enhanced antiproliferative potential and enhanced pharmacological profile, betulin derivatives are continuously investigated in scientific studies. The objective of the current study was to in vitro assess the antiproliferative properties of novel synthesized 1,2,4-triazole derivatives of diacetyl betulin. The compounds were investigated using three cancer cell lines: A375 (melanoma), MCF-7 (breast cancer), HT-29 (colorectal cancer), and HaCaT (human keratinocytes). Bet-TZ1 had the lowest recorded IC50 values (ranging from 22.41 to 46.92 μM after 48 h of exposure) than its precursor and other tested compounds in every scenario, with the highest cytotoxicity against the A375 cell line. Bet-TZ3 demonstrated comparable cytotoxicity to the previously mentioned compound, with an IC50 of 34.34 μM against A375. Both compounds caused apoptosis in tested cells, by inducing specific nuclear morphological changes and by increasing the expression of caspase 9, indicating significant cytotoxicity, which was consistent with the literature and viability evaluation. Bet-TZ1 and Bet-TZ3 inhibit cancer cell migration, with the former having a stronger effect than the latter. The HET−CAM test indicated that all compounds have no irritative potential, suggesting that they can be used locally.